Technology | Catheters | July 13, 2016

VentureMed Group Announce FDA Approval of FLEX Scoring Catheter

Surgical device provides alternative to balloon-based scoring for endovascular treatment of peripheral arterial disease

VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment

July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of peripheral arterial disease (PAD), announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Flex Scoring Catheter.

The catheter is an endovascular surgical device that precisely and dynamically scores any length atherosclerotic lesion as it passes through the femoral-popliteal anatomy. Flex provides an alternative to balloon-based scoring with a one-size-fits-all platform technology. 

VentureMed Group founder and chief science officer John Pigott, M.D., said the first-in-man trial of the device showed statistically significant improvement in ankle-brachial index scores at 30 days.  

FDA clearance of Flex, which received CE Mark in Europe in 2015, will provide interventionalists with a vessel preparation device that allows for effective dynamic linear scoring with a lower propensity for barotrauma or vessel wall damage. The design allows the operator to easily prepare a diseased vessel in a single insertion without the need for multiple balloon inflations.

The catheter is inserted over an 0.018-inch guidewire (6F compatible sheath) and threaded through the patient’s artery to a point just below the blockage. The surgeon pulls a thumb lever that exposes three precision atherotomes that are radially mounted at the tip of the catheter. As the catheter is drawn through the lesion, the blades make continuous micro-scores, relaxing the plaque. Next, the balloon is inflated to achieve luminal gain, allowing blood to flow freely.

For more information:

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init